Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
4(66.7%)
Phase 1
2(33.3%)
6Total
Early Phase 1(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03790891Early Phase 1Unknown

Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Role: lead

NCT04191941Early Phase 1Unknown

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Role: lead

NCT03720496Phase 1Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Role: lead

NCT03649529Early Phase 1Unknown

Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy

Role: lead

NCT03497533Phase 1Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19

Role: lead

NCT03910842Early Phase 1Unknown

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Role: lead

All 6 trials loaded